Clinical Trial Detail

NCT ID NCT01607905
Title Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Karyopharm Therapeutics, Inc
Indications

colorectal cancer

lung non-small cell carcinoma

peritoneal carcinoma

ovarian carcinoma

head and neck squamous cell carcinoma

fallopian tube carcinoma

prostate cancer

Advanced Solid Tumor

cervix carcinoma

astrocytoma

glioblastoma multiforme

Therapies

Selinexor

Age Groups: adult

No variant requirements are available.